According to a post on the FDA’s website, Kintara Therapeutics’ treatment of Diffuse Intrinsic Pontine Glioma received orphan designation. Reference Link
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on KTRA:
- Kintara Therapeutics Blasts Up after Children’s Brain Cancer Development
- Kintara Therapeutics regains compliance with Nasdaq listing rules
- Kintara Therapeutics Shares (NASDAQ: KTRA) Surge after Receiving Fast Track Designation
- Kintara Therapeutics grants FTD from FDA for REM-001
- Kintara Therapeutics Announces Fiscal 2023 First Quarter Financial Results and Provides Corporate Update